AR106325A1 - Agonistas del receptor de glucagón - Google Patents

Agonistas del receptor de glucagón

Info

Publication number
AR106325A1
AR106325A1 ARP160103112A ARP160103112A AR106325A1 AR 106325 A1 AR106325 A1 AR 106325A1 AR P160103112 A ARP160103112 A AR P160103112A AR P160103112 A ARP160103112 A AR P160103112A AR 106325 A1 AR106325 A1 AR 106325A1
Authority
AR
Argentina
Prior art keywords
receptor agonist
glucagon receptor
aib
ethoxy
pharmaceutically acceptable
Prior art date
Application number
ARP160103112A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR106325A1 publication Critical patent/AR106325A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto agonista del receptor de glucagón, caracterizado porque comprende la fórmula: YX¹QGTFX²SDYSKYLDX³KKAX⁴EFVX⁵WLLEX⁶X⁷ en donde X¹ es Aib; X² es T; X³ es Aib; X⁴ es K que se modificó químicamente a través de la conjugación al grupo e-amino de la cadena lateral de K con ([2-(2-amino-etoxi)-etoxi]-acetil)₂-(gGlu)ₐ-CO-(CH₂)ᵇ-CO₂H, en donde a es 1 y b es 18; X⁵ es A; X⁶ es E; y X⁷ está ausente; (SEC ID Nº 12); o una sal del mismo farmacéuticamente aceptable. Reivindicación 5: Un método para tratar el hígado graso, caracterizado porque comprende administrar a un bovino en necesidad del mismo, una cantidad efectiva del agonista del receptor de glucagón de conformidad con cualquiera de las reivindicaciones 1 - 4. Reivindicación 9: Una composición farmacéutica, caracterizada porque comprende el agonista del receptor de glucagón de conformidad con cualquiera de las reivindicaciones 1 - 4 y un portador, diluyente, o excipiente farmacéuticamente aceptable.
ARP160103112A 2015-10-26 2016-10-12 Agonistas del receptor de glucagón AR106325A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562246199P 2015-10-26 2015-10-26

Publications (1)

Publication Number Publication Date
AR106325A1 true AR106325A1 (es) 2018-01-03

Family

ID=57200152

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160103103A AR106318A1 (es) 2015-10-26 2016-10-11 Agonistas del receptor de glucagón
ARP160103112A AR106325A1 (es) 2015-10-26 2016-10-12 Agonistas del receptor de glucagón

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP160103103A AR106318A1 (es) 2015-10-26 2016-10-11 Agonistas del receptor de glucagón

Country Status (25)

Country Link
US (3) US9884093B2 (es)
EP (2) EP3368061B1 (es)
JP (3) JP6321299B2 (es)
KR (1) KR20180053747A (es)
CN (2) CN108348583B (es)
AR (2) AR106318A1 (es)
AU (2) AU2016344433B2 (es)
BR (2) BR112018006920A2 (es)
CA (2) CA3003242C (es)
DK (1) DK3368060T3 (es)
EA (2) EA201890676A1 (es)
ES (2) ES2809548T3 (es)
HR (1) HRP20201353T1 (es)
HU (1) HUE050859T2 (es)
IL (1) IL258092A (es)
LT (1) LT3368060T (es)
MX (2) MX2018005132A (es)
NZ (1) NZ740644A (es)
PL (2) PL3368060T3 (es)
PT (2) PT3368060T (es)
RS (1) RS60567B1 (es)
SI (1) SI3368060T1 (es)
TW (1) TWI622596B (es)
WO (2) WO2017074715A1 (es)
ZA (2) ZA201801756B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MX2018007859A (es) 2015-12-23 2018-11-09 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
MA49459A (fr) * 2017-06-21 2020-04-29 Amgen Inc Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
AU2018314773A1 (en) * 2017-08-09 2020-03-26 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
MX2020002977A (es) 2017-09-22 2020-11-06 Regeneron Pharma Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
TW202415675A (zh) * 2017-12-21 2024-04-16 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140021A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140025A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN112469431A (zh) * 2018-07-23 2021-03-09 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
US20210338779A1 (en) * 2018-10-04 2021-11-04 Hanmi Pharm. Co., Ltd Therapeutic use of glucagon and combination including the same
RS64438B1 (sr) * 2018-10-26 2023-09-29 Novo Nordisk As Stabilne kompozicije semaglutida i njihova upotreba
CN111171134B (zh) * 2018-11-12 2023-08-15 天津药物研究院有限公司 胰高血糖素衍生肽及其用途
US20200268835A1 (en) * 2019-02-27 2020-08-27 Novo Nordisk A/S Compounds For Use in NASH
PL3936142T3 (pl) * 2019-06-28 2024-05-06 Hanmi Pharm. Co., Ltd. Potrójny agonista wykazujący aktywność względem wszystkich pośród receptorów glukagonu, glp-1 oraz gip do leczenia chorób wątroby
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
PE20231309A1 (es) 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004932A (en) 1997-03-06 1999-12-21 Iowa State University Research Foundation, Inc. Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
CN1802386B (zh) 2003-06-12 2010-12-15 伊莱利利公司 Glp-1类似物融合蛋白质
AU2005203925A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
KR20150116465A (ko) * 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
CN102292347A (zh) * 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
US20130143798A1 (en) 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2011131646A1 (en) * 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
US8975223B2 (en) 2010-12-22 2015-03-10 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
MA34913B1 (fr) 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline
CN103596583B (zh) 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
EP2729493B1 (en) * 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
BR112014015681A2 (pt) * 2011-12-23 2019-09-24 Boehringer Ingelheim Int análogos de glucagon
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
JP6300239B2 (ja) 2012-06-21 2018-03-28 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
CN104662038B (zh) * 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
EP2895506A1 (en) 2012-09-17 2015-07-22 Imperial Innovations Limited Peptide analogues of glucagon and glp1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
KR20160021758A (ko) 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
JP6230352B2 (ja) 2013-09-19 2017-11-15 ユニ・チャーム株式会社 動物用排泄物処理材の製造方法および製造装置
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105745222A (zh) 2013-10-17 2016-07-06 西兰制药公司 酰化胰高血糖素类似物
TWI670281B (zh) * 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
US20150150643A1 (en) * 2013-12-02 2015-06-04 The Johns Hopkins University Personalized computational modeling of atrial fibrosis to guide catheter ablation of atrial fibrillation
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080149A1 (en) * 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
AR098616A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
AR098615A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
MX2016010599A (es) * 2014-02-18 2016-11-18 Novo Nordisk As Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
WO2016198604A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
MX2017016845A (es) 2015-06-30 2018-08-01 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑

Also Published As

Publication number Publication date
EA201890676A1 (ru) 2019-01-31
ZA201802371B (en) 2020-01-29
CN108135981B (zh) 2022-04-15
PL3368060T3 (pl) 2021-01-11
AU2016344434A1 (en) 2018-06-07
JP7211712B2 (ja) 2023-01-24
JP6321299B2 (ja) 2018-05-09
HUE050859T2 (hu) 2021-01-28
MX2018005129A (es) 2018-06-06
IL258092A (en) 2018-05-31
CA3003242A1 (en) 2017-05-04
EA038330B1 (ru) 2021-08-10
RS60567B1 (sr) 2020-08-31
CN108348583B (zh) 2022-06-03
EP3368060B1 (en) 2020-06-24
AU2016344433B2 (en) 2018-12-06
CA3003242C (en) 2022-08-09
EA201890634A1 (ru) 2018-10-31
CN108135981A (zh) 2018-06-08
AR106318A1 (es) 2018-01-03
MX2018005132A (es) 2018-06-06
PT3368061T (pt) 2019-10-28
HRP20201353T1 (hr) 2020-11-27
WO2017074715A1 (en) 2017-05-04
PT3368060T (pt) 2020-09-01
WO2017074714A1 (en) 2017-05-04
NZ740644A (en) 2019-10-25
ES2747908T3 (es) 2020-03-12
EP3368060A1 (en) 2018-09-05
US20180104312A1 (en) 2018-04-19
BR112018007225A2 (pt) 2018-10-16
US20170112904A1 (en) 2017-04-27
TWI622596B (zh) 2018-05-01
ZA201801756B (en) 2019-10-30
JP2018504376A (ja) 2018-02-15
KR20180053747A (ko) 2018-05-23
SI3368060T1 (sl) 2020-08-31
AU2016344434B2 (en) 2019-06-06
ES2809548T3 (es) 2021-03-04
BR112018006920A2 (pt) 2018-11-06
DK3368060T3 (da) 2020-08-24
US20170114115A1 (en) 2017-04-27
LT3368060T (lt) 2020-08-25
JP2018135346A (ja) 2018-08-30
CN108348583A (zh) 2018-07-31
EP3368061B1 (en) 2019-08-07
TW201726717A (zh) 2017-08-01
AU2016344433A1 (en) 2018-04-19
JP2018508464A (ja) 2018-03-29
US9884093B2 (en) 2018-02-06
CA3000538A1 (en) 2017-05-04
EP3368061A1 (en) 2018-09-05
JP6354017B2 (ja) 2018-07-11
PL3368061T3 (pl) 2020-03-31
US9764004B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
AR106325A1 (es) Agonistas del receptor de glucagón
PH12019501360A1 (en) Glp-1 receptor agonists and uses thereof
PE20220337A1 (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
CL2016002023A1 (es) “compuestos derivados de benzoato-4-(amidoamino)- sustituido con un grupo oxazol dicarboxilico, inhibidores de enteropeptidasa; composición farmacéutica que los comprende; y su uso en el tratamiento de obesidad y diabetes mellitus”. pct
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
CL2017002686A1 (es) Métodos para tratar o prevenir dolor de cabeza por migraña
PE20160225A1 (es) Modulacion de la inmunidad tumoral
CL2019000681A1 (es) Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk.
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
ECSP18026800A (es) Una composición para la acuicultura
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
WO2015054500A3 (en) Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
CL2019000270A1 (es) Composición de cannabis.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
PE20181176A1 (es) Composiciones biofarmaceuticas
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
AR115877A1 (es) Medios y métodos para el clivaje de la zearalenona
MX2017012068A (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.
CL2020001173A1 (es) Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas.
MX2019012952A (es) Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos.
MX2019011867A (es) Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.